Leuk Lymphoma. 1994 May;13(5-6):449-56. doi: 10.3109/10428199409049634.
Between 1985 and 1990, the French Cooperative Group on Chronic Lymphocytic Leukemia (CLL) randomized 287 stage B patients between intermittent chlorambucil plus prednisone (n = 140) or CHOP (n = 147), and 90 stage C patients between CHOP (n = 44) or CHOP plus methotrexate (n = 46). In stage B, although treatment response was improved with CHOP (p = 0.007, chi-square test), no difference in survival was observed between the two randomized groups (p = 0.33, score test). In stage C, no differences in treatment response and survival were shown, with median survival close to that reported with CHOP in the previous CLL-80 trial. These results associated with those from other groups raise the question whether the CHOP regimen, which has been consistently shown to improve response to therapy, is an effective treatment in advanced CLL patients.
1985年至1990年间，法国慢性淋巴细胞白血病（CLL）协作组将287例B期患者随机分为两组，一组接受间歇苯丁酸氮芥加泼尼松治疗（n = 140），另一组接受CHOP方案治疗（n = 147）；并将90例C期患者随机分为两组，一组接受CHOP方案治疗（n = 44），另一组接受CHOP加甲氨蝶呤治疗（n = 46）。在B期，虽然CHOP方案改善了治疗反应（p = 0.007，卡方检验），但两个随机分组之间的生存率没有差异（p = 0.33，计分检验）。在C期，治疗反应和生存率均无差异，中位生存期与之前CLL - 80试验中CHOP方案报告的相近。这些结果与其他研究组的结果共同引发了一个问题，即CHOP方案虽一直显示能改善治疗反应，但对晚期CLL患者是否为有效治疗方案。
